You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.
The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems."
The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.
The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
The RealStar Zika Virus RT-PCR Kit 1.0 has been listed by the World Health Organization as eligible for procurement agencies and member states.
The company's subsidiary Viracor-IBT can now run the real time, reverse transcriptase-PCR assay for patients meeting clinical or epidemiological criteria for Zika.
The results support the tests potential to more specifically predict high-risk prostate cancers, and lower the number of unnecessary prostate biopsies.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.